This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

Tax by Industry: Life Sciences


Life Sciences companies face enormous obstacles today. Internal issues include pressure to fuel a pipeline of promising new products and to successfully manage talent. External issues include government oversight, shareholder activism and the ever-growing number of competitors. The last thing you need is a surprise from the tax side of the business.

Managing tax uncertainty requires a multifaceted understanding of opportunities, risks and your company’s ability to integrate business issues into strategic planning. Driving an acceptable, sustainable, effective tax rate today frequently involves aligning business objectives, cross-border supply chain needs and technical proficiency. 

Well-executed transfer pricing policies can help to avoid a monumental and costly trap. And the interplay between tax risk and financial reporting has moved to the forefront with the issuance of Financial Accounting Standards Board's Interpretation No. 48.

With so many moving parts in the tax equation, it’s easy to unintentionally increase your tax exposure. We can help. Download the attached PDF to learn more.


Return to Tax by Industry

Featured insights

2014 U.S. Life Sciences Outlook: Challenges, trends and strategies that may shape your business
Deloitte LLP’s Terry Hisey, vice chairman and U.S. Life Sciences sector leader, discusses what 2014 could bring for life sciences companies.


10th Annual Deloitte Life Sciences Tax Conference
This two day conference is designed for pharmaceutical, biotechnology and medical device companies. Participants will enhance their technical skillset to help them succeed in today's demanding life sciences tax environment.  


IRS releases final regulations and interim guidance on Medical Device Excise Tax
On December 7, 2012, the U.S. Treasury Department published Final Regulations and additional interim guidance under Internal Revenue Code (“IRC”) section 4191 relating to the medical device excise tax (“MDET”) that was enacted as part of the Health Care and Education Reconciliation Act of 2010, in conjunction with the Patient Protection and Affordable Care Act.


Medical Device Excise Tax Services
The new Internal Revenue Code Section 4191 imposes a 2.3% excise tax on sales of any "taxable medical device" by the manufacturer, producer, or importer of the device. As a provision of the Affordable Care Act of 2010, Section 4191 is one of several revenue-raisers intended to offset the costs of broadening U.S. health care coverage.



California enacts partial sales and use tax exemption
On July 11, 2013, California Governor Edmund G. Brown Jr. signed Assembly Bill (“AB”) 93 and Senate Bill (“SB”) 90, enacting, among other provisions, a significant new tax incentive that is potentially worth more than $8 million annually to certain companies in the life science industry.



Last updated

Share this page

Email this Send to LinkedIn Send to Facebook Tweet this More sharing options

Stay connected